American Pain Society 2011

In a study presented at the American Pain Society’s 30th Annual Scientific Meeting, fentanyl buccal tablet was shown to be more effective than traditional short-acting opioids for the management of breakthrough pain in opioid-tolerant patients.

Duloxetine, pregabalin, and duloxetine + gabapentin were found to be safe and tolerable for the treatment of diabetic peripheral neuropathic pain, according to results presented today at the American Pain Society’s 30th Annual Scientific Meeting.

Variability in baseline breakthrough pain (BTP) has no impact on the analgesic response to sublingual fentanyl tablets or placebo, as demonstrated by an analysis presented at the American Pain Society’s 30th Annual Scientific Meeting.

In a trial designed to evaluate the analgesic effects of fulranumab in patients with chronic low back pain (cLBP), the agent did not demonstrate efficacy vs. placebo but was generally well tolerated, as reported by the study authors at the American Pain Society’s 30th Annual Scientific Meeting.

The MoxDuo combination of morphine and oxycodone may have a superior respiratory safety profile to that of equianalgesic morphine equivalent doses (MED) of either morphine or oxycodone alone, according to results presented at the American Pain Society’s 30th Annual Scientific Meeting.

The use of intravenous morphine + oxycodone had superior efficacy when compared with morphine alone, according to results presented at the American Pain Society’s 30th Annual Scientific Meeting.

Researchers at the American Pain Society’s 30th Annual Scientific Meeting discussed data from a review of spontaneous adverse events reported with Embeda (morphine sulfate and naltrexone HCl) treatment, with a focus on events potentially related to product tampering.

Milnacipran treatment resulted in improvements in pain and global status regardless of baseline pain severity or fibromyalgia severity, according to data presented at the American Pain Society’s 30th Annual Scientific Meeting.

Milnacipran treatment improves fatigue in fibromyalgia patients and improves pain regardless of baseline levels of fatigue, as reported by Philip Mease, MD, from the Seattle Rheumatology Associates and Swedish Medical Center, Seattle, WA, and colleagues at the American Pain Society’s 30th Annual Scientific Meeting.

At the American Pain Society’s 30th Annual Scientific Meeting, study data was presented showing that tapentadol ER does not significantly affect blood pressure (BP) or heart rate (HR) and thus, may be used for analgesia in patients with hypertension.